RGIN Stock Chart & Stats
$0.01
<$0.01(9900.00%)
At close: 4:00 PM EDT
$0.01
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume100.00K
Average Volume (3M)2.50K
Market Cap
$15.35K
Enterprise Value$643.70K
Total Cash (Recent Filing)$11.86M
Total Debt (Recent Filing)$642.92K
Price to Earnings (P/E)―
Beta21.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding153,483,050
10 Day Avg. Volume2,500
30 Day Avg. Volume2,500
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-0.09
Price to Sales (P/S)0.00
P/FCF Ratio-18.00
Enterprise Value/Market Cap41.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RGIN FAQ
What was Regenicin Inc’s price range in the past 12 months?
Regenicin Inc lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Regenicin Inc’s market cap?
Regenicin Inc’s market cap is $15.35K.
When is Regenicin Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regenicin Inc’s earnings last quarter?
Regenicin Inc released its earnings results on Feb 20, 2018. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is Regenicin Inc overvalued?
According to Wall Street analysts Regenicin Inc’s price is currently Overvalued.
Does Regenicin Inc pay dividends?
Regenicin Inc does not currently pay dividends.
What is Regenicin Inc’s EPS estimate?
Regenicin Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regenicin Inc have?
Regenicin Inc has 153,483,050 shares outstanding.
What happened to Regenicin Inc’s price movement after its last earnings report?
Regenicin Inc reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Regenicin Inc?
Currently, no hedge funds are holding shares in RGIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Regenicin Inc
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers. These innovative solutions aim to rejuvenate the characteristics of healthy human skin, finding application in burn therapy, chronic wound management, and various plastic surgery procedures. Incorporated in 2007 and based in Little Falls, New Jersey, the company was previously known as Windstar, Inc., adopting the Regenicin, Inc. name in July 2010.
Technical Analysis
Scinai Immunotherapeutics
―
Catheter Precision
―
Bone Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors